Instituto Ramón y Cajal de Investigación Sanitaria

What Instituto Ramón y Cajal de Investigación Sanitaria does

Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) is a publicly funded, non-profit health research institute founded in 2009 and headquartered within the Hospital Universitario Ramón y Cajal complex in Madrid, Spain. It operates as a consortium between the Madrid Health Service, three public universities (Complutense de Madrid, Alcalá de Henares, and Autónoma de Madrid), the Foundation for Biomedical Research of Ramón y Cajal University Hospital (FIBioHRC, founded 2003), and the Community of Madrid. IRYCIS is the first-accredited Health Research Institute in the Madrid region (accredited 2011; reaccredited 2017 and 2022) and holds the European Commission's HRS4R seal. The institute organizes 1,200+ research staff across 47 research groups (37 established and 5 emerging) and six priority areas spanning neurosciences, microbiology/immunology/infection, cancer, advanced medicine tools, chronic pathologies, and epidemiology/public health, generating 192 annual publications and supporting 154 active clinical trials as of the latest reported figures.

IRYCIS runs a translational research platform built around 11 Central Support Units (UCAs) and additional technical units covering biobanking and biomodels (PDX/organoid), translational genomics (MiSeq, NextSeq 550, NovaSeq 6000), lipidomics/proteomics (MALDI-TOF/TOF), spectral cytometry (Cytek CS Aurora 36-color), confocal microscopy, an ISO-8 environmental exposure chamber (the only one in Southern Europe), a Data Science unit (REDCap, ML, process mining), GCP-compliant clinical trial coordination (Phase I–IV) through SCReN and ECRIN, and a GMP-certified Cell Therapy Production Unit (UPTC) producing CAR-T cells, TILs, NK cells, and mesenchymal cells under AEMPS inspection. The institute operates the MISIÓN IRYCIS 2030 innovation program targeting four new therapies and three medical products by 2030, and holds 11 patent families including TLR4-specific aptamers (ApTOLL, Phase 1/2 completed, JAMA Neurology 2023), miRNA-based diagnostics, and MS biomarkers.

Revenue comes from public institutional grants, competitive national (ISCIII) and European (Horizon 2020, Horizon Europe) research projects, consortium co-funding (EATRIS-Plus €4.9M, REMEDI4ALL €25M, SCReN, ITEMAS), and pay-as-you-go service fees for biobank samples (€9.41–€14.39 per aliquot, €472.20 per PDX establishment) and technical consultancy (€20–€40 per hour). Customers are primarily internal IRYCIS researchers and external academic/clinical investigators accessing research infrastructure via direct service requests to unit coordinators, with pricing approved by the IRYCIS Governing Board. IRYCIS is also a WHO Collaborating Centre for Clinical Management of Leishmaniasis.

Name

Instituto Ramón y Cajal de Investigación Sanitaria

Legal name

Instituto Ramón y Cajal de Investigación Sanitaria

Website

https://irycis.org

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

IRYCIS is a publicly funded Madrid-based health research institute operating 11 specialized Central Support Units and 47 research groups delivering translational biomedical services—biobanking, genomics, cytometry, clinical trials, and GMP cell therapy—to internal researchers and external academic partners.

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA)

akta.pro secondary industry

Data Management, Biostatistics & Statistical Programming FSP (HLAGAOAB)

Keywords

• Biomedical research services
• Clinical trial support
• Translational genomics
• Biobanking services
• Cell therapy manufacturing

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Public Institutional Funding: IRYCIS is a publicly funded health research institute established through agreement between Madrid Health Service, three public universities (Alcalá de Henares, Complutense de Madrid, Autónoma de Madrid), the Foundation for Biomedical Research of Ramón y Cajal University Hospital (FIBioHRC), and the Community of Madrid. Primary funding comes from public grants, competitive research projects, and institutional support.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

IRYCIS is a publicly funded biomedical research institute that delivers scientific and technical services to internal and external researchers through 11 Central Support Units and 9 additional technical units. Its offerings span genomics, proteomics, lipidomics, metabolomics, bioinformatics, biobanking with PDX/organoid models, spectral cytometry, microscopy, GMP-certified cell therapy production, environmental exposure testing, clinical biostatistics, and Phase I–IV clinical trial coordination. Services are priced per unit with rates approved by the IRYCIS Governing Board and accessed via direct request to unit coordinators.

Product overview

Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) is a health research institute founded in 2009, comprising six member institutions (Madrid Health Service, Alcalá de Henares University, Complutense University, Autonomous University of Madrid, FIBioHRC Foundation, and Community of Madrid). The institute operates as a research services platform organized around 6 Priority Research Areas and 47 research groups, offering an extensive portfolio of scientific and technical services through 11 Central Support Units (UCAs) and 9 additional technical units. Core services include the Biobank and Biomodels unit for biological sample management and PDX/organoid generation; the Data Science Unit for clinical data analytics and machine learning; Translational Genomics for NGS sequencing and bioinformatics; Clinical Research and Clinical Trials units supporting phases I-IV; and the Cell Therapy Production Unit for GMP-grade advanced therapies. The MISIÓN IRYCIS 2030 innovation program drives translational development of new therapies and medical products.

Differentiator

Problem solved

Functional benefit

Products and services

• Central Support Units (UCAs) — Portfolio of Scientific and Technical Services A coordinated portfolio of 11 scientific and technical service units (including Animal Facility, Biobank, Clinical Biostatistics, Biomarkers, Lipidomics/Proteomics, Data Science, Clinical Studies, Translational Genomics, and Microscopy/Histology) providing specialized biomedical research infrastructure to internal and external researchers.
• Biobank and Biomodels

Quantifiable outcome

• 154 active clinical trials supported through UICEC and Early Phase Clinical Trials Unit
• +4 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature12 records

Partnerships

15 partnerships are on record, tiered core and minor.

• ITEMAS (Plataforma ISCIII de Dinamización e Innovación de las Capacidades Industriales del SNS)coreStrategic or Co-development PartnerIRYCIS Innovation Unit belongs to the ITEMAS platform funded by Instituto de Salud Carlos III, co-financed by FEDER. ITEMAS focuses on dynamization and innovation of industrial capacities of the National Health System and their effective transfer to the productive sector. Project PT23/00075.
• SCReN (Spanish Clinical Research Network)coreStrategic or Co-development PartnerUICEC (Clinical Research and Clinical Trials Unit) is part of the SCReN Support Platform for Clinical Research, providing scientific-technical support for independent clinical research development across Spain.
• ECRIN (European Clinical Research Infrastructure Network)coreStrategic or Co-development PartnerParticipation in SCReN allows UICEC to join ECRIN, expanding clinical research activity to European level. IRYCIS is a certified partner in this pan-European clinical research infrastructure.
• EATRIS (European Research Infrastructure for Translational Medicine)coreStrategic or Co-development PartnerEATRIS is a European infrastructure for translational medicine. IRYCIS is listed as a collaborating partner, providing access to European translational research network and shared capabilities.
• FIBioHRC (Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal)coreStrategic or Co-development PartnerFIBioHRC constitutes the technical, administrative, and sole management structure of IRYCIS. Founded 2003, authorized by Regional Government of Madrid Decree 187/2003. C.I.F.: G83726984. Responsible for effective management and constant support of IRYCIS, managing clinical research programs and projects.
• Universidad Complutense de Madrid (UCM)coreStrategic or Co-development PartnerIRYCIS founding member. Participation through groups from the Faculties of Pharmacy, Medicine, and Biological and Chemical Sciences. Contributes research groups to all 6 priority research areas.
• Universidad de Alcalá (UAH)coreStrategic or Co-development PartnerIRYCIS founding member. University that confers the university character upon the Hospital. Has eight groups associated with IRYCIS. Data Science Unit supervised by R+D+i Office based at Universidad de Alcalá.
• Universidad Autónoma de Madrid (UAM)coreStrategic or Co-development PartnerIRYCIS founding member. Participation through groups located in the Department of Material Physics of the Faculty of Physics. Contributes to IRYCIS through specialized research groups in physical sciences applied to biomedicine.
• Hospital Universitario Ramón y CajalcoreStrategic or Co-development PartnerIRYCIS founding member. Ramón y Cajal University Hospital constitutes the basic core of the Institute, providing the clinical research environment and patient population for translational research activities.
• Madrid Health Service (Servicio Madrileño de Salud)coreStrategic or Co-development PartnerIRYCIS founding member through which the hospital is part of the institute. One of the founding institutions that established IRYCIS by agreement on December 15, 2009.
• Community of Madrid - General Directorate of Research, Education and DocumentationcoreStrategic or Co-development PartnerIRYCIS founding member. Government body of the Community of Madrid in the field of regional scientific policy. One of the founding institutions that established IRYCIS.
• AptaTargetsminorStrategic or Co-development PartnerContract research collaboration for preclinical studies of aptamers including stability testing, toxicity assessment, plasma protein binding studies, and nanosphere formation effects.
• Aptus BiotechminorStrategic or Co-development PartnerContract research for preclinical studies of apMNKQ2 aptamer therapeutic candidate.
• 3TR (Horizon 2020)minorStrategic or Co-development PartnerEuropean research project in which IRYCIS Precision Immunological Markers unit participates, focusing on biomarkers associated with prognosis and response to treatment in multiple sclerosis.
• RD21/0002 (ISCIII Research Network)minorStrategic or Co-development PartnerISCIII Research Network in which IRYCIS participates for identification of biomarkers associated with prognosis and response to MS treatment.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer: Barcelona-based biomedical research institute anchored to Hospital Clínic, structurally similar to IRYCIS as a Spanish accredited IIS with multi-institutional consortium governance. Operates comparable translational research programs, clinical trials infrastructure, and biobank services.
• Vall d'Hebron Research Institute (VHIR): Major Barcelona hospital-affiliated biomedical research institute with comparable structure to IRYCIS. Provides similar services including clinical trials, biobanking, genomics platforms, and translational medicine capabilities within the Spanish NHS ecosystem.
• IBIMA - Instituto de Investigación Biomédica de Málaga: Málaga-based accredited Health Research Institute with similar consortium structure to IRYCIS, anchored to regional hospital system. Operates comparable Central Support Units for genomics, biobanking, and clinical trials.
• IIS La Fe - Instituto de Investigación Sanitaria La Fe: Valencia-based accredited Health Research Institute anchored to Hospital La Fe, with similar multi-institutional governance model and research service portfolio. Competes with IRYCIS for national Spanish research funding and clinical trial sponsorships.
• IdISSC - Instituto de Investigación Sanitaria del Hospital Clínico San Carlos: Madrid-based accredited Health Research Institute, directly comparable to IRYCIS as a fellow IIS in the Madrid region. Operates with similar Central Support Units structure and competes for the same regional research talent and grants.
• CIMA Universidad de Navarra: University of Navarra's Center for Applied Medical Research, a major Spanish biomedical research center. Comparable to IRYCIS with similar disease-focused research programs and translational pipelines from bench to clinical trials.
• IRB Barcelona - Institute for Research in Biomedicine: Barcelona-based biomedical research institute focused on fundamental and translational research. Comparable to IRYCIS in research scope and Spanish biomedical research standing, with similar structural biology and disease-oriented research programs.
• CNIO - Centro Nacional de Investigaciones Oncológicas: Spain's national cancer research center, a major Spanish biomedical research peer. Operates in overlapping oncology research areas with IRYCIS's Cancer priority area, with comparable genomics, PDX models, and translational research capabilities.
• CNIC - Centro Nacional de Investigaciones Cardiovasculares: Spain's national cardiovascular research center, comparable peer in the Spanish biomedical research ecosystem. Shares overlapping research themes with IRYCIS's cardiovascular research within Chronic Pathologies area and competes for national funding.

Others

• EATRIS - European Infrastructure for Translational Medicine: European research infrastructure consortium of which IRYCIS is a member. Functions as an ecosystem participant providing access to pan-European translational research networks and shared capabilities rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/InstitutoRamonyCajal
• LinkedInlinkedin.com/company/biobanco-huryc-irycis

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Instituto Ramón y Cajal de Investigación Sanitaria